Scisparc

Scisparc Operating Cash Flow

The Operating Cash Flow of Scisparc (SPRC) as of Oct 16, 2026 is -4.14 M USD. In the previous year, Operating Cash Flow was -5.10 M USD — a change of -18.95% (higher).

Operating Cash Flow

-4.14 MUSD

YoY

-18.95%

Last updated:

Operating Cash Flow of Scisparc is 2025 -4.14 M USD. Operating Cash Flow of Scisparc was 2024 -5.10 M USD. It decreases by -18.95% higher compared to the previous year.

The Scisparc Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-7.13 M USD
Jan 1, 2019
-4.70 M USD
Jan 1, 2020
-4.31 M USD
Jan 1, 2021
-5.06 M USD
Jan 1, 2022
-7.92 M USD
Jan 1, 2023
-5.89 M USD
Jan 1, 2024
-5.10 M USD
Jan 1, 2025
-4.14 M USD
The Scisparc Operating Cash Flow history
YEAROperating Cash FlowYoY
-4.14 MUSD-18.95%
-5.10 MUSD-13.30%
-5.89 MUSD-25.64%
-7.92 MUSD+56.43%
-5.06 MUSD+17.51%
-4.31 MUSD-8.28%
-4.70 MUSD-34.16%
-7.13 MUSD+55.75%
-4.58 MUSD+209.55%
-1.48 MUSD+11.86%
-1.32 MUSD-30.02%
-1.89 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? Scisparc Ltd., listed under the ticker SPRC with ISIN IL0010951403, is a biotechnology company headquartered in Tel Aviv-Yafo, Israel. The company operates in the healthcare sector and has a workforce of three employees. Scisparc Ltd. went public through an IPO on December 22, 2021. Its website is https://scisparc.com/. The company is engaged in the development of pharmaceutical products based on cannabinoid technologies, focusing on repurposing dronabinol for various medical conditions. Specific drug development programs include THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain treatment. Scisparc Ltd. is a clinical stage pharmaceutical company, indicating its focus on advancing drug candidates through clinical trials toward potential regulatory approval and commercialization. The company's activities are centered around leveraging cannabinoid-based approaches to address unmet medical needs in multiple therapeutic areas. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Operating Cash Flow of Scisparc is -4.14 M USD in 2025.

Operating Cash Flow of Scisparc changed from -5.10 M USD to -4.14 M USD, representing a -18.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Scisparc since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Scisparc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Scisparc

All Key Metrics — Scisparc